@article{81e123584f964cd49c8cefa7a8dae19f,
title = "Immune Checkpoint Inhibitor Toxicity in 2018",
author = "Johnson, {Douglas B.} and Sunandana Chandra and Sosman, {Jeffrey A.}",
note = "Funding Information: Funding/Support: Dr Johnson is funded by Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Johnson serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, Novartis, and Navigate BP, and receives research funding from Bristol-Myers Squibb and Incyte. Dr Chandra receives consulting fees as an advisory board member for Bristol-Myers Squibb, EMD Serono, Regeneron, and Novartis, and as a speaker{\textquoteright}s bureau member from Array Biopharma. Dr Sosman serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, and Genentech and receives research funding from Merck.",
year = "2018",
month = oct,
day = "23",
doi = "10.1001/jama.2018.13995",
language = "English (US)",
volume = "320",
pages = "1702--1703",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "16",
}